Shares of SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) climbed 2.7%, building on a previous gain of 2%, following the FDA approval of their drug, GOMEKLI, for the treatment of neurofibromatosis type ...
CHICAGO - CME Group (NASDAQ: CME) reported strong fourth-quarter results on Wednesday, beating earnings estimates and posting record full-year revenue as the derivatives marketpla ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback